Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Uptake of compounds that selectively kill multidrug-resistant cells: the copper transporter SLC31A1 (CTR1) increases cellular accumulation of the thiosemicarbazone NSC73306.

Fung KL, Tepede AK, Pluchino KM, Pouliot LM, Pixley JN, Hall MD, Gottesman MM.

Mol Pharm. 2014 Aug 4;11(8):2692-702. doi: 10.1021/mp500114e. Epub 2014 Jun 17.

2.

Contributions of microRNA dysregulation to cisplatin resistance in adenocarcinoma cells.

Pouliot LM, Shen DW, Suzuki T, Hall MD, Gottesman MM.

Exp Cell Res. 2013 Feb 15;319(4):566-74. doi: 10.1016/j.yexcr.2012.10.012. Epub 2012 Nov 5.

3.

Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family.

Pouliot LM, Chen YC, Bai J, Guha R, Martin SE, Gottesman MM, Hall MD.

Cancer Res. 2012 Nov 15;72(22):5945-55. doi: 10.1158/0008-5472.CAN-12-1400. Epub 2012 Aug 31.

4.

Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes.

Shen DW, Pouliot LM, Hall MD, Gottesman MM.

Pharmacol Rev. 2012 Jul;64(3):706-21. doi: 10.1124/pr.111.005637. Epub 2012 Jun 1. Review.

5.

The transcription factor GCF2 is an upstream repressor of the small GTPAse RhoA, regulating membrane protein trafficking, sensitivity to doxorubicin, and resistance to cisplatin.

Shen DW, Pouliot LM, Gillet JP, Ma W, Johnson AC, Hall MD, Gottesman MM.

Mol Pharm. 2012 Jun 4;9(6):1822-33. doi: 10.1021/mp300153z. Epub 2012 May 17.

Supplemental Content

Loading ...
Support Center